Wellboon Tablet contains Dydrogesterone 10 mg, a synthetic progestogen used primarily in the management of various gynecological conditions related to progesterone deficiency. It is indicated for the treatment of menstrual disorders such as irregular menstruation, secondary amenorrhea, and dysfunctional uterine bleeding. Additionally, Wellboon is employed in hormone replacement therapy to support the luteal phase in assisted reproductive techniques and to prevent threatened miscarriage in early pregnancy. Dydrogesterone acts by mimicking the effects of natural progesterone, promoting endometrial stability and regulating the menstrual cycle. The medication is generally well-tolerated, with a safety profile that supports its use in both short-term and long-term therapy under medical supervision. Common adverse effects may include mild gastrointestinal disturbances, headache, and breast tenderness, although serious side effects are rare. Wellboon Tablet should be prescribed after thorough evaluation of the patient’s hormonal status and contraindications, including known hypersensitivity to dydrogesterone or any component of the formulation. It is essential to follow the recommended dosage and duration of therapy to achieve optimal therapeutic outcomes. Regular monitoring by a healthcare professional is advised to assess efficacy and detect any potential adverse reactions.